Moleculin Biotech (NASDAQ:MBRX) Raised to Sell at StockNews.com

Moleculin Biotech (NASDAQ:MBRX) was upgraded by analysts at StockNews.com to a “sell” rating in a report issued on Wednesday.

A number of other analysts have also commented on the company. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Moleculin Biotech in a research note on Monday. Maxim Group raised shares of Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a report on Tuesday.

Moleculin Biotech Trading Down 1.9 %

Shares of NASDAQ:MBRX opened at $1.05 on Wednesday. Moleculin Biotech has a 52-week low of $0.40 and a 52-week high of $6.23. The company has a fifty day moving average of $1.30 and a 200-day moving average of $1.99.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.